Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akumin Inc. stock logo
AKU
Akumin
$0.18
$0.12
$1.90
$26.32M-0.721.38 million shs8.54 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19173,401 shs4.12 million shs
OpGen, Inc. stock logo
OPGN
OpGen
$3.52
$0.04
$5.25
$396K-1.668,849 shs143 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.38
-2.7%
$0.44
$0.26
$1.07
$86.99M1.123.15 million shs273,111 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akumin Inc. stock logo
AKU
Akumin
0.00%0.00%0.00%0.00%0.00%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%0.00%-69.91%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%0.00%-99.14%-99.20%-98.29%
Vaxart, Inc. stock logo
VXRT
Vaxart
0.00%+6.80%+9.51%-9.50%-36.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akumin Inc. stock logo
AKU
Akumin
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
2.7123 of 5 stars
3.55.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akumin Inc. stock logo
AKU
Akumin
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00689.47% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akumin Inc. stock logo
AKU
Akumin
$749.63M0.00N/AN/A$1.24 per share0.00
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M0.00N/AN/A($11.55) per share0.00
Vaxart, Inc. stock logo
VXRT
Vaxart
$47.40M1.84N/AN/A$0.26 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akumin Inc. stock logo
AKU
Akumin
-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/AN/A-1,140.36%N/A-287.58%N/A
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest AKU, OPGN, ENZ, and VXRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.08N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akumin Inc. stock logo
AKU
Akumin
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akumin Inc. stock logo
AKU
Akumin
17.02
0.99
0.99
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Akumin Inc. stock logo
AKU
Akumin
36.10%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Akumin Inc. stock logo
AKU
Akumin
20.51%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akumin Inc. stock logo
AKU
Akumin
3,63191.17 million72.47 millionNot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.91 million222.37 millionOptionable

Recent News About These Companies

Vaxart (VXRT) Expected to Announce Earnings on Thursday
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akumin stock logo

Akumin NASDAQ:AKU

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

OpGen stock logo

OpGen NASDAQ:OPGN

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.38 -0.01 (-2.71%)
As of 08/8/2025 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.